Cargando…

Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases

Gene therapy is an innovative approach in the field of regenerative medicine. This therapy entails the transfer of genetic material into a patient’s cells to treat diseases. In particular, gene therapy for neurological diseases has recently achieved significant progress, with numerous studies invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yujung, Lee, Sungwoo, Kim, Jieun, Kim, Chunggoo, Shim, Hyun Soo, Lee, Seung Eun, Park, Hyeok Ju, Kim, Jeongwon, Lee, Soohyun, Lee, Yong Kyu, Park, Sungho, Yoo, Junsang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222404/
https://www.ncbi.nlm.nih.gov/pubmed/37242096
http://dx.doi.org/10.3390/nano13101680
_version_ 1785049690076610560
author Chang, Yujung
Lee, Sungwoo
Kim, Jieun
Kim, Chunggoo
Shim, Hyun Soo
Lee, Seung Eun
Park, Hyeok Ju
Kim, Jeongwon
Lee, Soohyun
Lee, Yong Kyu
Park, Sungho
Yoo, Junsang
author_facet Chang, Yujung
Lee, Sungwoo
Kim, Jieun
Kim, Chunggoo
Shim, Hyun Soo
Lee, Seung Eun
Park, Hyeok Ju
Kim, Jeongwon
Lee, Soohyun
Lee, Yong Kyu
Park, Sungho
Yoo, Junsang
author_sort Chang, Yujung
collection PubMed
description Gene therapy is an innovative approach in the field of regenerative medicine. This therapy entails the transfer of genetic material into a patient’s cells to treat diseases. In particular, gene therapy for neurological diseases has recently achieved significant progress, with numerous studies investigating the use of adeno-associated viruses for the targeted delivery of therapeutic genetic fragments. This approach has potential applications for treating incurable diseases, including paralysis and motor impairment caused by spinal cord injury and Parkinson’s disease, and it is characterized by dopaminergic neuron degeneration. Recently, several studies have explored the potential of direct lineage reprogramming (DLR) for treating incurable diseases, and highlighted the advantages of DLR over conventional stem cell therapy. However, application of DLR technology in clinical practice is hindered by its low efficiency compared with cell therapy using stem cell differentiation. To overcome this limitation, researchers have explored various strategies such as the efficiency of DLR. In this study, we focused on innovative strategies, including the use of a nanoporous particle-based gene delivery system to improve the reprogramming efficiency of DLR-induced neurons. We believe that discussing these approaches can facilitate the development of more effective gene therapies for neurological disorders.
format Online
Article
Text
id pubmed-10222404
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102224042023-05-28 Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases Chang, Yujung Lee, Sungwoo Kim, Jieun Kim, Chunggoo Shim, Hyun Soo Lee, Seung Eun Park, Hyeok Ju Kim, Jeongwon Lee, Soohyun Lee, Yong Kyu Park, Sungho Yoo, Junsang Nanomaterials (Basel) Review Gene therapy is an innovative approach in the field of regenerative medicine. This therapy entails the transfer of genetic material into a patient’s cells to treat diseases. In particular, gene therapy for neurological diseases has recently achieved significant progress, with numerous studies investigating the use of adeno-associated viruses for the targeted delivery of therapeutic genetic fragments. This approach has potential applications for treating incurable diseases, including paralysis and motor impairment caused by spinal cord injury and Parkinson’s disease, and it is characterized by dopaminergic neuron degeneration. Recently, several studies have explored the potential of direct lineage reprogramming (DLR) for treating incurable diseases, and highlighted the advantages of DLR over conventional stem cell therapy. However, application of DLR technology in clinical practice is hindered by its low efficiency compared with cell therapy using stem cell differentiation. To overcome this limitation, researchers have explored various strategies such as the efficiency of DLR. In this study, we focused on innovative strategies, including the use of a nanoporous particle-based gene delivery system to improve the reprogramming efficiency of DLR-induced neurons. We believe that discussing these approaches can facilitate the development of more effective gene therapies for neurological disorders. MDPI 2023-05-19 /pmc/articles/PMC10222404/ /pubmed/37242096 http://dx.doi.org/10.3390/nano13101680 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chang, Yujung
Lee, Sungwoo
Kim, Jieun
Kim, Chunggoo
Shim, Hyun Soo
Lee, Seung Eun
Park, Hyeok Ju
Kim, Jeongwon
Lee, Soohyun
Lee, Yong Kyu
Park, Sungho
Yoo, Junsang
Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases
title Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases
title_full Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases
title_fullStr Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases
title_full_unstemmed Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases
title_short Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases
title_sort gene therapy using efficient direct lineage reprogramming technology for neurological diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222404/
https://www.ncbi.nlm.nih.gov/pubmed/37242096
http://dx.doi.org/10.3390/nano13101680
work_keys_str_mv AT changyujung genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT leesungwoo genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT kimjieun genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT kimchunggoo genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT shimhyunsoo genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT leeseungeun genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT parkhyeokju genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT kimjeongwon genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT leesoohyun genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT leeyongkyu genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT parksungho genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases
AT yoojunsang genetherapyusingefficientdirectlineagereprogrammingtechnologyforneurologicaldiseases